BRPI0908396A2 - quinolinas como inibidores de farnesil pirofosfato sintase - Google Patents
quinolinas como inibidores de farnesil pirofosfato sintaseInfo
- Publication number
- BRPI0908396A2 BRPI0908396A2 BRPI0908396-0A BRPI0908396A BRPI0908396A2 BR PI0908396 A2 BRPI0908396 A2 BR PI0908396A2 BR PI0908396 A BRPI0908396 A BR PI0908396A BR PI0908396 A2 BRPI0908396 A2 BR PI0908396A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinolines
- farnesyl pyrophosphate
- pyrophosphate synthase
- synthase inhibitors
- compounds
- Prior art date
Links
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 title abstract 3
- 101710125754 Farnesyl pyrophosphate synthase Proteins 0.000 title abstract 3
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003248 quinolines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08152046.2 | 2008-02-28 | ||
| EP08152046 | 2008-02-28 | ||
| PCT/EP2009/052314 WO2009106586A1 (en) | 2008-02-28 | 2009-02-26 | Quinolines as inhibitors of farnesyl pyrophosphate synthase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0908396A2 true BRPI0908396A2 (pt) | 2019-03-06 |
Family
ID=39636965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908396-0A BRPI0908396A2 (pt) | 2008-02-28 | 2009-02-26 | quinolinas como inibidores de farnesil pirofosfato sintase |
Country Status (11)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2754058A1 (en) * | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| WO2013090929A1 (en) * | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | Amino quinoline derivatives inhibitors of hcv |
| CN104142378B (zh) * | 2014-07-29 | 2015-12-30 | 华南理工大学 | 薄层色谱法半定量测定氨基甲酸乙酯的方法 |
| EP3698797A1 (en) | 2017-10-16 | 2020-08-26 | Tsinghua University | Mevalonic acid pathway inhibitor and pharmaceutical composition thereof |
| CN111440161B (zh) * | 2020-05-15 | 2023-04-14 | 中国药科大学 | 一种具有par4拮抗活性的二环杂芳基类化合物及其应用 |
| CN112980809B (zh) * | 2021-03-17 | 2023-04-11 | 云南中烟工业有限责任公司 | 一种烟草法尼基焦磷酸合酶基因及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254544A (en) * | 1992-09-25 | 1993-10-19 | E. R. Squibb & Sons, Inc. | Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method |
| US20020151459A1 (en) * | 2000-02-25 | 2002-10-17 | Merck & Co., Inc. | Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase |
-
2009
- 2009-02-26 US US12/918,880 patent/US20120094958A1/en not_active Abandoned
- 2009-02-26 BR BRPI0908396-0A patent/BRPI0908396A2/pt not_active IP Right Cessation
- 2009-02-26 MX MX2010009518A patent/MX2010009518A/es not_active Application Discontinuation
- 2009-02-26 KR KR1020107019046A patent/KR20100124732A/ko not_active Withdrawn
- 2009-02-26 AU AU2009218468A patent/AU2009218468A1/en not_active Abandoned
- 2009-02-26 JP JP2010548111A patent/JP2011514893A/ja active Pending
- 2009-02-26 EP EP09715302A patent/EP2250152A1/en not_active Withdrawn
- 2009-02-26 EA EA201001362A patent/EA201001362A1/ru unknown
- 2009-02-26 WO PCT/EP2009/052314 patent/WO2009106586A1/en not_active Ceased
- 2009-02-26 CA CA2717011A patent/CA2717011A1/en not_active Abandoned
- 2009-02-26 CN CN2009801064544A patent/CN101959865A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010009518A (es) | 2010-09-14 |
| EP2250152A1 (en) | 2010-11-17 |
| US20120094958A1 (en) | 2012-04-19 |
| EA201001362A1 (ru) | 2011-04-29 |
| CA2717011A1 (en) | 2009-09-03 |
| CN101959865A (zh) | 2011-01-26 |
| JP2011514893A (ja) | 2011-05-12 |
| AU2009218468A1 (en) | 2009-09-03 |
| KR20100124732A (ko) | 2010-11-29 |
| WO2009106586A1 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| BR112014027236A2 (pt) | pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| BR112013000868A2 (pt) | derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4 | |
| NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
| BR112013022761B8 (pt) | Compostos moduladores heterocíclicos de síntese de lipídios, suas composições e usos | |
| BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
| CL2009000503A1 (es) | Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida. | |
| CR20120659A (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer | |
| ECSP11010885A (es) | Heteroarilos sustituidos | |
| BR112012010186B8 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos | |
| BR122019015876B8 (pt) | compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos | |
| BR112012023315A2 (pt) | compostos inibidores de enzima | |
| BR112013020996A8 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| CL2011000936A1 (es) | Proceso de preparacion de compuestos derivados de l-alanina protegidos, utiles como intermediarios de la sintesis de compuestos moduladores opioides mu/delta. | |
| BR112012023836A2 (pt) | composto tricíclicos e inibidores de pbk contendo os mesmos | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| BR112015018242B1 (pt) | método de controle de pragas | |
| ECSP12012230A (es) | Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores | |
| PH12013501922A1 (en) | Protein kinase inhibitors | |
| UY33549A (es) | Quinolil aminas como agentes inhibidores de las quinasas | |
| BR112012017393A2 (pt) | derivados de 2,5,7-oxazolpirimidina substituída | |
| BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |